Voyager Therapeutics,Inc. (NASDAQ:VYGR) Files An 8-K Entry into a Material Definitive Agreement

Voyager Therapeutics,Inc. (NASDAQ:VYGR) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement.

On June1, 2018 (the “Amendment Date”), Voyager Therapeutics,Inc. (the “Company”) and UP 45/75 Sidney Street, LLC (the “75 Landlord”) entered into a third amendment (the “75 Third Amendment”) to the lease agreement by and between the Company and the 75 Landlord, dated as of April1, 2014 (as amended to date, the “75 Lease”), for the Company’s office and laboratory space located at 75 Sidney Street (the “75 Premises”) in Cambridge, Massachusetts. Additionally, on the Amendment Date, the Company and UP 64 Sidney Street, LLC (the “64 Landlord”) entered into a first amendment (the “64 First Amendment”) to the lease agreement by and between the Company and the 64 Landlord, dated as of December23, 2015 (as amended to date, the “64 Lease”), for the Company’s office and laboratory space located at 64 Sidney Street (the “64 Premises”) in Cambridge, Massachusetts.

75 Lease Amendment

The 75 Third Amendment expands the 75 Premises to include an additional 17,931 rentable square feet (the “75 Expansion Area”) for a total of 47,493 rentable square feet at the 75 Premises. The 75 Third Amendment also extends the term of the 75 Lease for the period from January1, 2025 through November30, 2026 (the “75 Extended Term”). The Company will pay annual fixed rent on the 75 Expansion Area commencing thirty (30) days following the date of delivery of the 75 Expansion Area (such date of delivery, the “75 Expansion Commencement Date”), which is anticipated to be November16, 2018. Annual fixed rent for the 75 Expansion Area shall be $83.00 per rentable square foot through the first anniversary of the 75 Expansion Commencement Date and thereafter shall increase three percent (3%) annually. During the 75 Extended Term, annual fixed rent for the remainder of the 75 Premises shall be at the same rate per square foot as the annual fixed rent for the 75 Expansion Area. Subject to customary conditions and in accordance with the 75 Lease, the 75 Third Amendment also provides a tenant improvement allowance of $15.00 per rentable square foot for the 75 Expansion Area.

The foregoing description of the 75 Third Amendment does not purport to be complete and is qualified in its entirety by reference to the 75 Third Amendment, a copy of which is attached as Exhibit10.1 hereto and is incorporated herein by reference.

64 Lease Amendment

The 64 First Amendment extends the original term of the 64 Lease from January1, 2025 through November30, 2026 (the “64 Extended Term”). During the 64 Extended Term, annual fixed rent for the 64 Premises from January1, 2025 through November15, 2025 shall be $99.11 per rentable square foot and for the period from November16, 2025 through November30, 2026 shall be $102.08 per rentable square foot.

The foregoing description of the 64 First Amendment does not purport to be complete and is qualified in its entirety by reference to the 64 First Amendment, a copy of which is attached as Exhibit10.2 hereto and is incorporated herein by reference.

Item 1.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

Description

10.1

Third Amendment to Lease Agreement, by and between Voyager Therapeutics,Inc. and UP 45/75 Sidney Street, LLC, dated June 1, 2018.

10.2

First Amendment to Lease Agreement, by and between Voyager Therapeutics,Inc. and UP 64 Sidney Street, LLC, dated June 1, 2018.


Voyager Therapeutics, Inc. Exhibit
EX-10.1 2 a18-14788_1ex10d1.htm EX-10.1 Exhibit 10.1   Execution Copy   THIRD AMENDMENT TO LEASE AGREEMENT   THIS THIRD AMENDMENT TO LEASE AGREEMENT (“Third Amendment”) made and entered into this 1st day of June,…
To view the full exhibit click here

About Voyager Therapeutics,Inc. (NASDAQ:VYGR)

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company. The Company is focused on developing life-changing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s product pipeline includes programs for Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich’s ataxia, Huntington’s disease, spinal muscular atrophy (SMA), frontotemporal dementia, Alzheimer’s disease and severe, chronic pain. Its products include VY-AADC01 for Advanced Parkinson’s Disease, VY-SOD101 for Monogenic amyotrophic lateral sclerosis (ALS), VY-FXN01 for Friedreich’s Ataxia, VY-HTT01 for Huntington’s Disease and VY-SMN101 for spinal muscular atrophy (SMA). VY-AADC01 consists of the AAV2 capsid, which has been used in multiple adeno-associated virus (AAV) gene therapy clinical trials for various diseases, and the cytomegalovirus promoter that drives expression of the AADC transgene.

An ad to help with our costs